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● Using LC-MS/MS, we found that pancreatic cancer proliferation can 
be slowed down using the drug Brequinar as a DHODH inhibitor, 
which reduces the number of metabolites necessary to create 
pyrimidines and allow proliferation.
INTRODUCTION
RESULTS METHODS
● Brequinar inhibits DHODH 
causing an increase in 
metabolites upstream and a 
depletion in metabolites 
downstream of DHODH.
● Brequinar caused a significant 
difference (p-value<0.05) in 
several de novo pathway 
metabolites.
● Significantly altered metabolites 
are shown in this volcano plot.
CONCLUSIONS
● Brequinar inhibits DHODH and causes pyrimidine depletion, 
consequently arresting pancreatic cancer cell proliferation. 
● Brequinar warrants an investigation as potential treatment for 
pancreatic cancer.
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● Procedural methods: Took human PDAC cell line S2-013 and treated 
group A with Brequinar and group B with the control and then 
extracted the metabolites for both groups. Next, we used LC-MS/MS. 
LC-MS/MS, separates mixtures with multiple components, mass 
spectrometry provides the structural identity of the individual 
components with high molecular specificity and detection sensitivity
● Statistical methods: Raw data was analyzed using metaboanalyst 2.0 
software to generate heat map and volcano plot. 
● Purpose: Determine if Brequinar can be effectively used to inhibit 
Dihydroorotate dehydrogenase (DHODH) and slow pancreatic cancer 
cell proliferation.
● Significance: Cancerous cells can negatively affect bodily functions 
and become fatal if left untreated and proliferate. Pyrimidine 
nucleotide biosynthesis is a critical metabolic pathway for malignant 
cell transformation and proliferation that is activated by several well-
known oncogenes.
● How our research fits a need: DHODH is an enzyme in the inner 
mitochondrial membrane, which plays a role in the de novo pyrimidine 
biosynthesis pathway. By inhibiting DHODH, pyrimidines are depleted, 
arresting cancer proliferation. The effectiveness of Brequinar 
treatment in pancreatic cancer can be shown in metabolomic data 
collected using liquid chromatography-mass spectrometry (LC-
MS/MS).
● Hypothesis: We predicted pancreatic cancer cells treated with 
Brequinar would have more upstream metabolites and fewer 
downstream metabolites of DHODH in the de novo pyrimidine 
biosynthesis pathway.
Fig. 6 Each data point on the volcano plot 
corresponds to a particular metabolite. Red 
indicates a metabolites that have > 1.5 fold 
change and a p-value < 0.05.
Fig. 5 Heat map comparing the abundance of  
metabolites between the Brequinar group (left) 
and the control (right). Red intensity indicates a 
higher abundance while blue intensity indicates a 
lower abundance.
Fig. 4 Visual representation of the de novo
pyrimidine biosynthesis pathway. A dashed arrow 
next to a metabolite indicates an 
increase/decrease after Brequinar treatment.
Fig. 1 Visual representation of purines and 
pyrimidines.
Fig. 3 Visual representation of 
the LC-MS/MS metabolomics 
protocol.
Fig. 2 Visual representation of several different 
oncogenes that upregulate pyrimidine 
metabolism.
⇡
⇡ ⇡
⇡
⇡
⇡
⇡
